Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
Abstract Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of the nucleotide analogue tenofovir, which acts intracellularly to inhibit HIV replication. Whereas TDF converts to tenofovir in plasma and may cause kidney and bone toxicity, TAF mostly converts to tenofovir...
Saved in:
Main Authors: | Aida N. Kawuma (Author), Roeland E. Wasmann (Author), Phumla Sinxadi (Author), Simiso M. Sokhela (Author), Nomathemba Chandiwana (Author), Willem D. F. Venter (Author), Lubbe Wiesner (Author), Gary Maartens (Author), Paolo Denti (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021) -
Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
by: Andrew Hill, et al.
Published: (2018) -
Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
by: Eric H. Decloedt, et al.
Published: (2021) -
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
by: Squillace N, et al.
Published: (2020) -
Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
by: Emmanouil Sinakos, et al.
Published: (2024)